B K Bang

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2020 · 595 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

Jonathan I. Silverberg, D. Toth, Thomas Bieber et al. · British Journal of Dermatology · 2020 · 317 citations · Full text

Medicine, Dermatology, Immunology +17

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

Robert Gniadecki, B K Bang, Lars Erik Bryld et al. · British Journal of Dermatology · 2014 · 278 citations

Pharmacy, Dermatology, Pharmacotherapy +16

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

Joanne R Chalmers, Kim S Thomas, Christian Apfelbacher et al. · British Journal of Dermatology · 2018 · 160 citations · Full text

Medicine, Dermatology, Pediatrics +15

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study

C. Paul, Linda Stein Gold, F. Cambazard et al. · Journal of the European Academy of Dermatology and Venereology · 2016 · 112 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +13